Readings Newsletter
Become a Readings Member to make your shopping experience even easier.
Sign in or sign up for free!
You’re not far away from qualifying for FREE standard shipping within Australia
You’ve qualified for FREE standard shipping within Australia
The cart is loading…
Prostate cancer occurs in the walnut shaped prostate gland, which generates seminal fluid that transports and nourishes the sperm cells in males. It can be diagnosed through various methods such as digital rectal exam, magnetic resonance imaging, prostate-specific antigen test, ultrasound imaging and prostate biopsy. Majority of people with early-stage prostate cancer can benefit from treatment options like irradiation or radical prostatectomy. Androgen deprivation therapy (ADT) is the typical systemic therapy for individuals with advanced prostate cancer. Although ADT provides a short term remission, most patients eventually develop castration-resistant prostate cancer (CRPC). Effective therapy becomes limited after prostate cancer cells lose their sensitivity to ADT. Several novel alternatives for the treatment of CRPC include taxane, CYP17 inhibitor and AR antagonist. This book contains some path-breaking studies on human prostate cancer cells. It aims to shed light on some of the unexplored aspects of their detection, growth and treatment. This book is a vital tool for all researching and studying this topic.
$9.00 standard shipping within Australia
FREE standard shipping within Australia for orders over $100.00
Express & International shipping calculated at checkout
Prostate cancer occurs in the walnut shaped prostate gland, which generates seminal fluid that transports and nourishes the sperm cells in males. It can be diagnosed through various methods such as digital rectal exam, magnetic resonance imaging, prostate-specific antigen test, ultrasound imaging and prostate biopsy. Majority of people with early-stage prostate cancer can benefit from treatment options like irradiation or radical prostatectomy. Androgen deprivation therapy (ADT) is the typical systemic therapy for individuals with advanced prostate cancer. Although ADT provides a short term remission, most patients eventually develop castration-resistant prostate cancer (CRPC). Effective therapy becomes limited after prostate cancer cells lose their sensitivity to ADT. Several novel alternatives for the treatment of CRPC include taxane, CYP17 inhibitor and AR antagonist. This book contains some path-breaking studies on human prostate cancer cells. It aims to shed light on some of the unexplored aspects of their detection, growth and treatment. This book is a vital tool for all researching and studying this topic.